Back

KRT17 stabilizes EPN1 via inhibiting SMURF1-mediated ubiquitination to modulate Wnt/β-catenin signaling output and stem-like traits in ovarian cancer

Du, G.; Li, B.; Zhao, R.; Tong, H.; He, Y.; Ding, J.

2026-02-25 cancer biology
10.64898/2026.02.20.707140 bioRxiv
Show abstract

BackgroundOvarian cancer (OC) progression and chemoresistance are closely linked to dysregulated oncogenic signaling, including Wnt/{beta}-catenin pathways that contribute to cancer stem-like traits. However, the upstream mechanisms connecting cytoskeletal regulation to Wn/{beta}-catenin signaling in OC remain incompletely understood. Keratin 17 (KRT17), a type I intermediate filament protein, has been implicated in tumor progression, but its mechanistic role in OC requires clarification. MethodsGene Expression Omnibus (GEO) datasets and clinical specimens were analyzed to assess KRT17 and EPN1 expression and prognostic significance. Functional assays, xenograft models, co-immunoprecipitation, ubiquitination analyses, and rescue experiments with wild-type and ubiquitination-resistant EPN1 mutants were performed to investigate molecular mechanisms. ResultsKRT17 expression was elevated in OC tissues and correlated with poor patient survival. KRT17 depletion suppressed proliferation, migration, stem-like properties, tumor growth, and cisplatin resistance. Mechanistically, KRT17 interacted with EPN1 and weakened its association with the E3 ligase SMURF1, reducing SMURF1-mediated ubiquitination at lysine 107 and preventing proteasomal degradation. Stabilized EPN1 was associated with increased {beta}-catenin abundance and stemness-associated markers, and enhanced self-renewal capacity. ConclusionsThese findings identify a KRT17-EPN1 axis that links intermediate filament dynamics to ubiquitin-dependent regulation of EPN1 stability and Wnt/{beta}-catenin signaling outputs in ovarian cancer.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
British Journal of Cancer
42 papers in training set
Top 0.1%
22.5%
2
Cancers
200 papers in training set
Top 0.4%
10.1%
3
International Journal of Cancer
42 papers in training set
Top 0.1%
6.8%
4
PLOS ONE
4510 papers in training set
Top 28%
6.3%
5
npj Precision Oncology
48 papers in training set
Top 0.2%
3.6%
6
Cancer Research
116 papers in training set
Top 0.8%
3.6%
50% of probability mass above
7
Molecular Cancer Research
42 papers in training set
Top 0.1%
3.2%
8
Scientific Reports
3102 papers in training set
Top 41%
3.1%
9
Clinical Cancer Research
58 papers in training set
Top 0.6%
2.6%
10
Oncogene
76 papers in training set
Top 0.9%
1.9%
11
JCI Insight
241 papers in training set
Top 3%
1.8%
12
BMC Medicine
163 papers in training set
Top 4%
1.7%
13
Cancer Medicine
24 papers in training set
Top 0.8%
1.7%
14
Frontiers in Oncology
95 papers in training set
Top 2%
1.5%
15
Neoplasia
22 papers in training set
Top 0.4%
1.2%
16
Molecular Oncology
50 papers in training set
Top 0.6%
1.2%
17
Gastroenterology
40 papers in training set
Top 1%
1.2%
18
Translational Oncology
18 papers in training set
Top 0.2%
1.1%
19
Annals of Oncology
13 papers in training set
Top 0.8%
0.9%
20
Cell Reports
1338 papers in training set
Top 31%
0.9%
21
BMC Cancer
52 papers in training set
Top 3%
0.7%
22
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.6%
0.7%
23
Breast Cancer Research
32 papers in training set
Top 0.5%
0.7%
24
NAR Cancer
36 papers in training set
Top 0.1%
0.7%
25
Journal of Clinical Medicine
91 papers in training set
Top 7%
0.7%
26
Communications Biology
886 papers in training set
Top 26%
0.7%
27
eBioMedicine
130 papers in training set
Top 5%
0.7%
28
Cell Reports Medicine
140 papers in training set
Top 8%
0.7%
29
Cell Communication and Signaling
35 papers in training set
Top 1%
0.7%
30
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.4%
0.6%